Product Description
VLX600 is preferentially active against slow/non proliferating cells in the metabolically compromised microenvironment in solid tumors, normally resistant to chemotherapy. The molecular mechanism of action of VLX600 is associated with its strong chelation of cellular iron. (Sourced from: https://vivolux.com)
Mechanisms of Action: OxPhos Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vivolux AB
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| V13-11045 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2016-12-28 |
41% |